Clinical Trial

Necrotizing Enterocolitis and Bowel Perforation in Very Preterm Infants - Long-term Follow up

Study acronym: NOR-NEC
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 3, 2025 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Necrotizing enterocolitis (NEC) is a gastrointestinal syndrome characterized by transmural inflammation and necrosis of the large and/or small bowel and subsequent intramural gas-forming organisms into the intestinal wall. Some preterm infants also develop spontaneous intestinal perforations (SIP) without the classical bowel inflammation/necrosis seen in NEC. NEC and SIP can be challenging to differentiate. Severe cases of both conditions require surgery and often bowel resection, but mortality due to SIP seems lower. Studies looking at "long-term prognosis" of infants with NEC and bowel perforation have mainly assessed outcome until 2-7 years of age. The primary school years is a vulnerable period for ex-preterm children. Disruption in learning and social integration is of great importance for their quality of life (QoL), but little data exist in this age group. Moreover, nutritional deficits (e.g. cobalamin- or iron-deficiency may impact cognitive development, but this has not been investigated in this "high-risk" population in school age. Authors of a recent systematic review on gastrointestinal sequel after NEC-surgery thus called for "more high-quality studies assessing long-term follow-up". In this project we will study the long-term impact of surgery for NEC and bowel perforation in preterm infants, both with a quality of life (QoL) perspective and with a focus on development, growth, nutrition and persistent gastrointestinal problems.
Trial Details
NCT Number NCT06757582
Lead Sponsor University Hospital of North Norway
Conditions Necrotizing Enterocolitis, Intestinal Perforation, Premature Infant Disease
Enrollment 150 participants
Start Date 2025-02-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-03